Evidence map›Paper›PMID 39386208›Full record

ArticleFrontiers in immunology2024

Plasma adenosine deaminase-1 and -2 activities are lower at birth in Papua New Guinea than in The Gambia but converge over the first weeks of life.

Thomas S Kouyate, Athena N Nguyen, Alec L Plotkin, Rebeca Ford, Olubukola T Idoko, Oludare A Odumade, Geraldine Masiria, Joe Jude, Joann Diray-Arce, Kerry McEnaney and 9 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Thomas S Kouyate *Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.
Athena N Nguyen *Precision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.
Alec L PlotkinPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.
Rebeca FordPapua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Olubukola T IdokoVaccines & Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, Gambia.
Oludare A OdumadePrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.
Geraldine MasiriaPapua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Joe JudePapua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Joann Diray-ArcePrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.
Kerry McEnaneyPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.
Al OzonoffPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.
Hanno SteenPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.
Tobias R KollmannTelethon Kids Institute, Subiaco, WA, Australia.
Peter C RichmondWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.
Anita H J van den BiggelaarWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, WA, Australia.
Beate KampmannVaccines & Immunity Theme, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Banjul, Gambia.
William PomatPapua New Guinea Institute of Medical Research, Goroka, Papua New Guinea.
Ofer LevyPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.
Kinga K SmolenPrecision Vaccines Program, Department of Pediatrics, Boston Children's Hospital, Boston, MA, United States.

Funding

Transcriptomics to define biomarkers of neonatal vaccine immunogenicityU19AI118608 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI LEVY, OFER · 2017 to 2021
$24.7M
Proteomics and Metabolomics Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthmaU19AI168643 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI OFER LEVY · 2022 to 2026
$10.0M
NIAID NIH HHS U19 AI118608NIAID NIH HHS U19 AI168643
6 · The paper itself

Abstract

Introduction: Dynamic cellular and molecular adaptations in early life significantly impact health and disease. Upon birth, newborns are immediately challenged by their environment, placing urgent demands on the infant immune system. Adenosine deaminases (ADAs) are enzymatic immune modulators present in two isoforms - ADA-1 and ADA-2. Infants exhibit low ADA activity, resulting in high plasma adenosine concentrations and a consequent anti-inflammatory/anti-Th1 bias. While longitudinal studies of plasma ADA have been conducted in infants in The Gambia (GAM), little is known regarding ADA trajectories in other parts of the world. Methods: Herein, we characterized plasma ADA activity in an infant cohort in Papua New Guinea (PNG; n=83) and compared to ontogeny of ADA activity in a larger cohort in GAM (n=646). Heparinized peripheral blood samples were collected at day of life (DOL) 0, DOL7, DOL30, and DOL128. Plasma ADA-1, ADA-2, and total ADA activities were measured by chromogenic assay. Results: Compared to GAM infants, PNG infants had significantly lower ADA-1 (0.9-fold), ADA-2 (0.42-fold), and total ADA (0.84-fold) activities at birth which converged by DOL30. Discussion: Overall, discovery of a distinct baseline and a consistent pattern of increasing plasma ADA activity in early life in two genetically and geographically distinct populations validates and extends previous findings on the robustness of early life immune ontogeny.

Indexed as

Adenosine DeaminaseFemaleGambiaHumansInfantInfant, NewbornIntercellular Signaling Peptides and ProteinsMalePapua New GuineaADA2 protein, humanADA protein, humanAdenosine DeaminaseIntercellular Signaling Peptides and Proteinsadenosine deaminaseglobal healthimmune developmentinfantontogeny

Identifiers

PMID39386208
PMCPMC11461337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.